Access TOC
Get a SampleOctober 2023
Primary Cell Culture Market (By Product: Primary Cell, Reagents, Supplements, Media; By Application: Vaccine Production, Stem Cell Therapy, Cancer Research; By Cell Type: Animal Cells, Human Cells) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global primary cell culture market size was estimated at USD 7.03 billion in 2023 and it is projected to hit around USD 21.51 billion by 2033, expanding at a CAGR of 11.81% during the forecast period 2024 to 2033.
The U.S. primary cell culture market size reached USD 4.93 billion in 2023 and is anticipated to be worth around USD 15.38 billion by 2033, poised to grow at a CAGR of 12.02% from 2024 to 2033.
North America held the largest share of 52.14% in 2023 and is anticipated to keep this position during the forecast period. The growth of the region is driven by factors such as the high cost of healthcare, the increasing prevalence of chronic diseases, an aging population, and government funding support. Market players' focus on developing innovative cell culture applications, the availability of diverse cell types, and their interactions also contribute to the expansion of the market in the region.
Meanwhile, the Asia Pacific region is projected to experience the fastest growth over the forecast period. This growth is primarily attributed to decreased costs of stem cell transplantation, which drives strong demand in the region. Additionally, significant research and development activities conducted by scientists in the area contribute to its expansion. For example, in March 2020, researchers at China's Centre for Disease Control (CDC) successfully cultured SARS-CoV-2 by means of lung airway cells grown in human tissue culture systems.
The Europe primary cell culture market size surpassed USD 1.65 billion in 2023 and is projected to reach USD 5.38 billion by 2033.
| Year | Market Size (USD Billion) |
| 2023 | 1.65 |
| 2024 | 1.87 |
| 2025 | 2.10 |
| 2026 | 2.37 |
| 2027 | 2.67 |
| 2028 | 3.01 |
| 2029 | 3.40 |
| 2030 | 3.83 |
| 2031 | 4.31 |
| 2032 | 4.86 |
| 2033 | 5.38 |
Primary Cell Culture Market Overview
The rise in chronic diseases such as cancer, infections, autoimmune disorders, cardiovascular diseases, diabetes mellitus, and nephrological diseases is mostly to blame for the market expansion. Because of the growth in research, primary cell cultures have been widely used. The American Cancer Society estimates that there will be 16.9 million cancer patients and survivors in 2020. 71.0 million persons worldwide have chronic hepatitis C infection, according to the WHO (2020). Consequently, the need for research into cutting-edge therapeutics is being driven by the increasing number of chronic ailments being identified, which is anticipated to accelerate market expansion in the next years.
The market for primary cell culture is expanding in part because primary cell cultures are being used for in-vitro testing and medication screening. These are produced from tissues, allowing researchers to examine the cellular structure in the in vivo setting and demonstrate how normally they operate. As a result, they are employed as model systems to research drug and toxin effects, aging processes, signaling investigations, metabolic processes, and cell biochemistry and physiology.
Demand for primary cell culture is rising as a result of expanding research into developing new treatments. The need for primary cell culture is also growing as a result of the study into the characterization and isolation of viruses. The market for primary cell culture products is being driven by growing academic tissue culture research activities worldwide in the field of life sciences. In addition, the primary cell culture product makers continue to benefit from the rising prevalence of chronic disorders such as diabetes mellitus, autoimmune diseases, cancer, chronic infections, nephrological diseases, and cardiovascular diseases. Additionally, the prevalence of cancer is continuously rising on a global scale.
| Report Coverage | Details |
| Market Size in 2023 | USD 7.03 Billion |
| Market Size by 2033 | USD 21.51 Billion |
| Growth Rate from 2024 to 2033 | CAGR of 11.81% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product, By Application, and By Cell Type |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Drivers:
Increasing cancer research
9.6 million people died from cancer, which is now the biggest cause of mortality in the world. Primary cells play a significant role in this study since the frequency of this illness has increased, necessitating substantial research for diagnosis and therapy. These cells are excellent models for finding cancer biomarkers and testing medications. They are also utilized to comprehend the molecular mechanisms behind cellular communication. In cancer research, initial cells are frequently subjected to high chemicals, radiation doses, and viruses, which cause these cells to become cancer by introducing oncogenes and causing genetic abnormalities. This makes it possible to study the altered signaling pathways of malignant cells as well as the molecular-level process and the etiology of cancer.
Restraints:
Concerns regarding primary cell culture contamination
One of the most frequent issues in cell culture labs is primary cell culture contamination. Utilizing tainted cells puts cell physiology at peril, frequently yields inaccurate findings, or results in the loss of distinctive cell lines. In addition to slowing down cell metabolism, contamination in cell cultures may infect finished goods like vaccinations, which can completely ruin a batch. As a result, businesses restrict their funding for cell-based research and choose alternate techniques for drug screening.
Opportunities:
Advancing biomedical research using primary cells in 3D cultures
Due to their nearly exact resemblance to the original donor tissue, primary cells are thought to be more physiologically representative than cell lines. This makes it clearer that primary cells used in 3D cell structures are better adept than cell lines to create physiologically accurate representations of in vivo multicellular settings. Because they produce results that are more precise than those of conventional cell lines, primary cells are widely used in 3D cultures. For instance, primary hepatocytes grown in a monolayer on plastic undergo undifferentiation and pass away after four days.
Impact of COVID-19:
The COVID-19 epidemic is helping to fuel the expansion of the primary cell culture sector. Primary cell culture is being used more often by researchers to study the illness. Epithelium cell culture models that have been standardized and characterized are making it easier to comprehend how the coronavirus eroded the physical barrier. These models can assist in simulating the features and operations of the respiratory system, which might result in a breakthrough for the translation of a research finding into a medicinal application. Additionally, it has been demonstrated that the primary immune cell culture is highly helpful in the investigation of the immunological repertoire to generate antibodies and antigens for the COVID-19 virus. Researchers from the German Primate Centre in Gottingen discovered that the COVID-19 virus might prevent infection in lung cells by using TMPRSS2, a serine protease inhibitor. With the primary cell culture experiment, the findings have been confirmed.
The primary cell culture market was led by the reagents and supplements category, which also generated the most revenue at 36% in 2023. The segment's expansion is the result of its regular use in primary cell culture-based research and manufacture. Because primordial cells are naturally delicate, the reagents and supplements are thought to be essential for their development.
The creation of novel products like growth factors and cytokines is also a role in the segment's expansion. For instance, in October 2020, Safi Biosolutions, Inc. and iBio, Inc., a biotechnology business with headquarters in the United States, struck a strategic partnership to work together on the creation of cytokines and growth factors utilizing iBio's FastPharming System.
In 2023, the primary cell culture market was dominated by the vaccine manufacturing sector, which also had the biggest revenue share. This expansion can be attributed to the growing use of primary animal cultures for the viral generation that is used to create various vaccinations, including those for hepatitis B and measles. Additionally, this has reduced the costs related to using animal models for vaccination testing. Over the course of the projected period, the stem cell treatment market is anticipated to grow at a profitable CAGR. The expansion of the market is linked to scientists' increased interest in employing stem cells in various research initiatives. Researchers' perspectives on primary cells are being quickly altered by studies involving adult, induced, and embryonic stem cells. In addition, stem cell-based treatments have demonstrated considerable promise and potential in treating a variety of conditions, including diabetes, dentistry, ophthalmic illnesses, and neurodegenerative diseases. As a result, it is further projected that the market would be driven by the growing application of such therapies.
In 2023, the market for primary cell culture was dominated by the animal cells sector, which contributed 61% of total revenue. One of the main drivers of the market's expansion is the expanding use of primary cells of animal origin for the creation of vaccines. The creation of vaccinations against rabies, chickenpox, polio, measles, and hepatitis B has utilized animal-derived primary cultures.
For the projection period, the human cells sector is anticipated to experience significant expansion. The increasing use of primary cultures made from human tissue for cancer research is largely to blame for the segment's rise. To enable the physiologically appropriate research of cancer, primary human cancer cells are obtained from a range of tissue types, including the brain, skeletal muscle, and connective tissue. These cultures can be used as a reliable tool for preclinical and clinical investigations in cancer research because they closely match the behavior and phenotype of cancer tissues.
Segment Covered in the Report:
By Product
By Application
By Cell Type
By Geography
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
October 2023
July 2024
December 2023
October 2023